Daily Roundup

BIO.ASX AUB.ASX BMT.ASX DSE.ASX FOS.ASX

Biome Launches Activated Therapeutics Range

Microbiome health company Biome Australia Limited (ASX: BIO) has some exciting news to share. They've launched a brand-new line called Activated Therapeutics, which will offer four specialized natural medicine products with evidence-based therapeutic applications. This complements their flagship Activated Probiotics brand, allowing Biome to broaden its therapeutic offerings beyond just probiotics.

The Activated Therapeutics range includes products like Oestro-ISO for perimenopausal symptoms, Synbio-GOS for gastrointestinal repair, Pepti-BIOTIC for acid reflux, and Macro-PRO for weight management and nutritional support. These will be available through health practitioners and community pharmacies, helping to deliver better patient outcomes through effective natural medicines.

Biome has already presented the new Activated Therapeutics line to its existing network of distributors, and they're thrilled with the strong support for launching these products starting in June 2025.

AUB Group Forecasts Strong FY25 Earnings

Over at AUB Group Limited (AUB), the news is also quite positive. The ASX200 listed insurance broking and underwriting group is forecasting its underlying net profit after tax (UNPAT) for the 2025 financial year to come in towards the top end of its previously announced outlook range of AUD 190.0 million to AUD 200.0 million.

This improved earnings guidance is thanks to favorable trading momentum, as well as AUB's assumptions around the usual seasonality and renewal cycle, favorable foreign exchange rates, and an effective USD hedging program covering around 85% of its USD operational flows.

Beamtree Reports Strong Q3 FY25 Trading Update

Healthcare technology company Beamtree Holdings Ltd (ASX: BMT) is also having a great quarter. In its Q3 FY25 trading update, Beamtree highlighted major contract wins, including launching the Evolve Collaborative with the NHS Confederation in England and expanding its autonomous coding product across Australia, the UK, and Canada.

Beamtree is targeting over 20% annual recurring revenue (ARR) growth for the full 2025 financial year, with improved profitability in the second half. The company remains confident in delivering ARR of $30 million going into the next financial year, backed by a strong pipeline of opportunities across all its markets and products.

FIRB Approval Received and Extension of Time to Hold AGM

Lastly, Dropsuite Ltd (ASX:DSE) has some administrative updates to share. The company has received FIRB approval for the proposed acquisition of Dropsuite by NinjaOne Australia, satisfying a key condition precedent for the scheme. Dropsuite's directors unanimously recommend shareholders vote in favor of the scheme.

Dropsuite has also been granted an extension by ASIC to hold its 2025 Annual General Meeting, from the original deadline of 31 May to 31 July. This will enable the AGM to be held once the outcome of the scheme is known.

That's the news roundup for today, folks. Lots of positive developments across these ASX-listed companies, from new product launches to strong earnings guidance and major contract wins. Stay tuned for more updates from the world of business and finance.